PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect

Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers

(2010) K. G. Roberts et al.   CANCER RESEARCH

Mechanisms of MYC stabilization in human malignancies

(2010) Melissa R. Junttila et al.   CELL CYCLE

Highly Phosphorylated FOXO3A Is an Adverse Prognostic Factor in Acute Myeloid Leukemia

(2010) S. M. Kornblau et al.   CLINICAL CANCER RESEARCH

Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms

(2010) A M Martelli et al.   LEUKEMIA

A B56γ mutation in lung cancer disrupts the p53-dependent tumor-suppressor function of protein phosphatase 2A

(2010) G P Shouse et al.   ONCOGENE

SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia

(2009) I. Cristobal et al.   BLOOD

The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia

(2009) N Gallay et al.   LEUKEMIA

Jak2 inhibition deactivates Lyn kinase through the SET–PP2A–SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients

(2009) A K Samanta et al.   ONCOGENE

Optimal induction and post-remission therapy for AML in first remission

(2009) J. M. Rowe   Hematology-American Society of Hematology Education Program

Multiple pathways regulated by the tumor suppressor PP2A in transformation

(2008) Jukka Westermarck et al.   TRENDS IN MOLECULAR MEDICINE

Molecular Genetic Pathways as Therapeutic Targets in Acute Myeloid Leukemia

(2008) T. Haferlach   Hematology-American Society of Hematology Education Program